The SGLT2 inhibitor canagliflozin attenuates mitochondrial oxidative stress and alterations of calcium handling induced by high glucose in human cardiac fibroblasts

Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections

González, P., Lozano, P., Ros, G., & Solano, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119352 · Cited by 891 · see citing works

NAD(P)H Oxidase 4 Mediates Transforming Growth Factor-β1–Induced Differentiation of Cardiac Fibroblasts Into Myofibroblasts

Cucoranu, I., Clempus, R., Dikalova, A., Phelan, P. J., Ariyan, S., Dikalov, S., & Sorescu, D. (2005) · Circulation Research · doi:10.1161/01.res.0000187457.24338.3d · Cited by 786 · see citing works

Diabetic vascular diseases: molecular mechanisms and therapeutic strategies

Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 762 · see citing works

Myofibroblasts and Fibrosis

Gibb, A., Lazaropoulos, M. P., & Elrod, J. W. (2020) · Circulation Research · doi:10.1161/circresaha.120.316958 · Cited by 443 · see citing works

Fibroblasts in the Infarcted, Remodeling, and Failing Heart

Humeres, C. D., & Frangogiannis, N. G. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.006 · Cited by 406 · see citing works

Mitochondrial oxidative stress promotes atrial fibrillation

Xie, W., Santulli, G., Reiken, S. R., Yuan, Q., Osborne, B. W., Chen, B.-X., & Marks, A. R. (2015) · Scientific Reports · doi:10.1038/srep11427 · Cited by 303 · see citing works

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01703-8 · Cited by 245 · see citing works

Mitochondrial dysfunction in fibrotic diseases

Li, X., Zhang, W. Y., Cao, Q., Wang, Z., Zhao, M., Xu, L., & Zhuang, Q. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00316-9 · Cited by 226 · see citing works

Heart failure in diabetes

Jankauskas, S. S., Kansakar, U., Varzideh, F., Wilson, S. M., Mone, P., Lombardi, A., Gambardella, J., & Santulli, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154910 · Cited by 221 · see citing works

Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells

Uthman, L., Homayr, A., Juni, R. P., Spin, E., Kerindongo, R. P., Boomsma, M., Hollmann, M. W., Preckel, B., Koolwijk, P., van Hinsbergh, V. W. M., et al. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000178 · Cited by 212 · see citing works

Pivotal Role of TGF-β/Smad Signaling in Cardiac Fibrosis: Non-coding RNAs as Effectual Players

Saadat, S., Noureddini, M., Mahjoubin‐Tehran, M., Nazemi, S., Shojaie, L., Aschner, M., Maleki, B., Abbasi‐Kolli, M., Moghaddam, H. R., Alani, B., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.588347 · Cited by 198 · see citing works

Thioredoxin Reductase-2 Is Essential for Keeping Low Levels of H2O2 Emission from Isolated Heart Mitochondria

Stanley, B. A., Sivakumaran, V., Shi, S., McDonald, I., Lloyd, D., Watson, W. H., Aon, M. A., & Paolocci, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.284612 · Cited by 197 · see citing works

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus

Figtree, G. A., Rådholm, K., Barrett, T. D., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Matthews, D. R., Shaw, W. C., & Neal, B. C. (2019) · Circulation · doi:10.1161/circulationaha.119.040057 · Cited by 164 · see citing works

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart

Lim, V. G., Bell, R. M., Arjun, S., Kolatsi‐Joannou, M., Long, D. A., & Yellon, D. M. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.10.002 · Cited by 162 · see citing works

Mitochondrial NLRP3 Protein Induces Reactive Oxygen Species to Promote Smad Protein Signaling and Fibrosis Independent from the Inflammasome

Bracey, N. A., Gershkovich, B., Chun, J., Vilaysane, A., Meijndert, H. C., Wright, J. R., Fedak, P. W. M., Beck, P. L., Muruve, D. A., & Duff, H. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.550624 · Cited by 156 · see citing works

TGF-β signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves

Hagler, M. A., Hadley, T. M., Zhang, H., Mehra, K. N., Roos, C. M., Schaff, H. V., Suri, R. M., & Miller, J. D. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt083 · Cited by 143 · see citing works

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases

Tsai, K., Chen, Y., Chiou, T. T., Chu, T., Li, L., Ng, H., Lee, W., & Lee, C. (2021) · Antioxidants · doi:10.3390/antiox10081166 · Cited by 135 · see citing works

Effects of canagliflozin on human myocardial redox signalling: clinical implications

Kondo, H., Akoumianakis, I., Badi, I., Akawi, N. A., Kotanidis, C. P., Polkinghorne, M., Stadiotti, I., Sommariva, E., Antonopoulos, A. S., Carena, M. C., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab420 · Cited by 119 · see citing works

Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways

Hasan, R., Lasker, S., Hasan, A., Zerin, F., Zamila, M., Chowdhury, F. I., Nayan, S. I., Rahman, M. M., Khan, F., Subhan, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71449-1 · Cited by 112 · see citing works

Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model

Hasan, R., Lasker, S., Hasan, A., Zerin, F., Zamila, M., Parvez, F., Rahman, M. M., Khan, F., Subhan, N., & Alam, M. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-71599-2 · Cited by 111 · see citing works

Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling

Zhang, Y., Lin, X., Chu, Y., Chen, X., Du, H., Zhang, H., Xu, C., Xie, H. B., Ruan, Q., Lin, J., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01312-8 · Cited by 99 · see citing works

Cardiomyocyte-Derived Exosomal MicroRNA-92A Mediates Post-Ischemic Myofibroblast Activation Both in Vitro and Ex Vivo

Wang, X., Morelli, M. B., Matarese, A., Sardu, C., & Santulli, G. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12584 · Cited by 88 · see citing works

The Role of Cardiac Fibrosis in Diabetic Cardiomyopathy: From Pathophysiology to Clinical Diagnostic Tools

Pan, K., Hsu, Y., Chang, S., Chung, C., & Lin, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108604 · Cited by 80 · see citing works

Ca2+ Signaling in Cardiac Fibroblasts and Fibrosis-Associated Heart Diseases

Feng, J., Armillei, M. K., Yu, A. S., Liang, B. T., Runnels, L. W., & Yue, L. (2019) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd6040034 · Cited by 75 · see citing works

Endothelial α1‐adrenoceptors regulate neo‐angiogenesis

Ciccarelli, M., Santulli, G., Campanile, A., Galasso, G., Cervero, P., Altobelli, G. G., Cimini, V., Pastore, L., Piscione, F., Trimarco, B., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707637 · Cited by 68 · see citing works

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

Ali, A., Mekhaeil, B., Biziotis, O., Tsakiridis, E. E., Ahmadi, E., Wu, J., Wang, S. J. H., Singh, K., Menjolian, G., Farrell, T. J., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05289-w · Cited by 64 · see citing works

Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit

Santulli, G., Basilicata, M. F., Simone, M. D., Giudice, C. D., Anastasio, A., Sorriento, D., Saviano, M., Gatto, A. D., Trimarco, B., Pedone, C., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-7 · Cited by 56 · see citing works

Ketone Bodies Rescue Mitochondrial Dysfunction Via Epigenetic Remodeling

Gambardella, J., Jankauskas, S. S., Kansakar, U., Varzideh, F., Avvisato, R., Prevete, N., Sidoli, S., Mone, P., Wang, X., Lombardi, A., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.03.014 · Cited by 55 · see citing works

Cardio-renal benefits of sodium–glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence

Aguilar-Gallardo, J. S., Correa, A. A., & Contreras, J. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab056 · Cited by 51 · see citing works

Mitochondrial quality control in cardiac fibrosis: Epigenetic mechanisms and therapeutic strategies

Lin, L.-C., Tu, B., Song, K., Liu, Z., Sun, H., Zhou, Y., Sha, J.-M., Yang, J., Ye, Z., Zhao, J., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155626 · Cited by 51 · see citing works

The effect of SGLT2 inhibitors on the endothelium and the microcirculation: from bench to bedside and beyond

Dimitriadis, K. S., Adamopoulou, E., Pyrpyris, N., Sakalidis, A., Leontsinis, I., Manta, E., Mantzouranis, E., Beneki, E., Σουλαϊδόπουλος, Σ., Konstantinidis, D., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad053 · Cited by 50 · see citing works

miR-7 Regulates GLP-1-Mediated Insulin Release by Targeting β-Arrestin 1

Matarese, A., Gambardella, J., Lombardi, A., Wang, X., & Santulli, G. (2020) · Cells · doi:10.3390/cells9071621 · Cited by 43 · see citing works

Cardiac fibroblast activation and hyaluronan synthesis in response to hyperglycemia and diet-induced insulin resistance

Gorski, D. J., Petz, A., Reichert, C., Twarock, S., Grandoch, M., & Fischer, J. W. (2019) · Scientific Reports · doi:10.1038/s41598-018-36140-6 · Cited by 41 · see citing works

Redox homeostasis in cardiac fibrosis: Focus on metal ion metabolism

Liu, Z., Liu, Z., Lin, L.-C., Song, K., Tu, B., Ye, Z., Yang, J., Zhao, J., & Tao, H. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103109 · Cited by 37 · see citing works

SGLT2 inhibitors in cardiovascular medicine

Varzideh, F., Kansakar, U., & Santulli, G. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab039 · Cited by 30 · see citing works

Canagliflozin, an SGLT-2 inhibitor, ameliorates acetic acid-induced colitis in rats through targeting glucose metabolism and inhibiting NOX2

Morsy, M. A., Khalaf, H. M., Rifaai, R. A., Bayoumi, A. M. A., Khalifa, E. M. M. A., & Ibrahim, Y. F. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111902 · Cited by 30 · see citing works

A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure

Bradley, J., Spaletra, P. M., Li, Z., Sharp, T. E., Goodchild, T. T., Corral, L. G., Fung, L. M., Chan, K. W. H., Sullivan, R. W., Swindlehurst, C. A., et al. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00603.2017 · Cited by 22 · see citing works

Protective transcriptional mechanisms in cardiomyocytes and cardiac fibroblasts

Brand, C. S., Lighthouse, J. K., & Trembley, M. A. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.04.023 · Cited by 21 · see citing works

Diabetes Induces Cardiac Fibroblast Activation, Promoting a Matrix‐Preserving Nonmyofibroblast Phenotype, Without Stimulating Pericyte to Fibroblast Conversion

Alex, L., Tuleta, I., Hanna, A., & Frangogiannis, N. G. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027463 · Cited by 21 · see citing works

TRIM35 triggers cardiac remodeling by regulating SLC7A5-mediated amino acid transport and mTORC1 activation in fibroblasts

Yang, B., Wang, Z., Niu, K., Li, T., Tong, T., Li, S., Su, L., Wang, Y., Shen, C., Jin, X., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01826-0 · Cited by 18 · see citing works

Sodium Glucose Co-Transporter 2 Inhibitors Improve Renal Congestion and Left Ventricular Fibrosis in Rats With Hypertensive Heart Failure

Nakatsukasa, T., Ishizu, T., Ouchi, M., Murakoshi, N., Sato, K., Yamamoto, M., Kawanishi, K., Seo, Y., & Ieda, M. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0105 · Cited by 16 · see citing works

Exploiting GRK2 Inhibition as a Therapeutic Option in Experimental Cancer Treatment: Role of p53-Induced Mitochondrial Apoptosis

Gambardella, J., Fiordelisi, A., Santulli, G., Ciccarelli, M., Cerasuolo, F. A., Sala, M., Sommella, E., Campiglia, P., Illario, M., Iaccarino, G., et al. (2020) · Cancers · doi:10.3390/cancers12123530 · Cited by 15 · see citing works

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Li, J., Arnott, C. G., Heerspink, H. J. L., MBiostat, Q. L., Cannon, C. P., Wheeler, D. C., Charytan, D. M., Barraclough, J., Figtree, G. A., Agarwal, R., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.025045 · Cited by 11 · see citing works

The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts

Varzideh, F., Jankauskas, S. S., Jain, U., Soderquist, L., Agyapong, E. D., Kansakar, U., & Santulli, G. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae050 · Cited by 6 · see citing works

SGLT2 inhibitors and cardiac fibrosis: A comprehensive review

Karakasis, P., Theofilis, P., Vlachakis, P. K., Apostolos, A., Milaras, N., Ktenopoulos, N., Grigoriou, K., Klisic, A. N., Karagiannidis, E., Fyntanidou, B., et al. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103149 · Cited by 28 · see citing works

SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration

Noh, S. W., Ryu, H. S., Kim, Y. H., & Oh, B. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2786 · Cited by 10 · see citing works

Immunology of heart failure with preserved ejection fraction

Wang, B., Jankauskas, S. S., Mone, P., Varzideh, F., & Santulli, G. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2587180 · Cited by 9 · see citing works

Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells

Pan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2 · see citing works

Effects of dapagliflozin on ventricular remodeling and prognosis in older females with heart failure with preserved ejection fraction: A single-center prospective study

Huang, J., Chen, J., Xu, S., Zhang, H., Ni, M., Wang, A., & Shi, Y. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112926 · Cited by 2 · see citing works

Effects of canagliflozin on cardiovascular disease risk factors in patients with type 2 diabetes: a systematic review and meta-analysis

Aftabi, H., & Aftabi, R. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01984-3 · Cited by 1 · see citing works

Ipragliflozin exerts anti-fibrotic effects via a novel multi-pathway mechanism: Targeting TLR4/NF-κB /TGF-β1 cascade

Alsugoor, M. H., Alsuhaymi, N., Moustafa, P. E., Madani, M. E., Afifi, N. A., Derzawy, A., Ibrahim, N. E., Fayed, H. M., & Awdan, S. A. E. (2026) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2026.106964 · Cited by 1 · see citing works

SGLT2 Inhibitors Promote Diabetic Wound Healing Via AMPK/AKT/mTORC1-Regulated Endothelial Angiogenesis

Bestepe, F., Ghanem, G. F., Kelly, C., Huseynli, K., Richards, D. V., Barber, R., Zamary, A., Sahu, P., Salehi, P., Huggins, G. S., et al. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.126.324596 · Cited by 1 · see citing works

Analysis of Allele-Specific Expression Highlights Novel Participants of Empagliflozin-Driven Effects on T2DM-Associated Regulatory Pathways

Korbolina, E. E., Gubina, M., Bryzgalov, L. O., Degtyareva, A. O., Evseenko, A., Antonseva, E. V., Korbut, A. I., Rykova, E. Y., Klimontov, V. V., Kzhyshkowska, J. G., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167202

Key safety outcomes of SGLT2 inhibitors versus DPP ‐4 inhibitors in general and vulnerable participants with T2DM : A target trial emulation study

Yen, C., Li, P., Wu, C., Tsai, C., Chen, J., Jenq, C., Hsu, H., Kuo, C., See, L., & Yang, H. (2026) · Diabetic Medicine · doi:10.1111/dme.70504

Targeting Metabolic Drivers of Cardiovascular Disease: Insights for Therapeutic Innovation

Kansakar, U., Hyman, M., Volpe, E., Mone, P., Qin, Y., & Santulli, G. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s611903

Abstract 15303: The SGLT2 Inhibitor Canagliflozin Attenuates Fibrosis and Mitochondrial Dysfunction Induced by Hyperglycemia in Isolated Primary Human Cardiac Fibroblasts

Varzideh, F., Jankauskas, S. S., Kansakar, U., Lombardi, A., & Santulli, G. (2023) · Circulation · doi:10.1161/circ.148.suppl_1.15303

Canagliflozin Orchestrates the Hepato-Cardiac Protection Axis via Upregulation of Liver-Derived FGF21: A Study in Mice and a Randomized Controlled TrialPreprint

Tsai, Z.-Y., Lee, C. C., Huang, T.-C., Vairaperumal, T., Chang, C.-S., Hsu, L.-W., Liu, Y. W., Wu, C., & Liu, P. (2026) · Research Square · doi:10.21203/rs.3.rs-9286602/v1

The sodium–glucose co-transporter 2 inhibitor canagliflozin, attenuates cardiac fibrosis and function in inflammatory dilated cardiomyopathy

Wang, J., Zhang, Z., & Yang, Y. J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag785.790

Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function.

Dasari, D., Goyal, S., Penmetsa, A., Sriram, D., & Dhar, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175720 · Cited by 21 · see citing works

Canagliflozin Attenuates Hypertrophy, Oxidative Stress, and Lipid Profile through the Connective Tissue Growth Factor Pathway in Isoprenaline-induced Cardiac Injury

Garg, G., Gari, M., Sharma, M., Aneesha, V. A., Sharma, A., Lingaraju, M. C., Parida, S., Kumar, A., Singh, V., Sonal, et al. (2026) · Journal of Veterinary Pharmacology and Toxicology · doi:10.4103/jvpt.jvpt_10_25